As an outcome of chronic liver disease, liver fibrosis involves the activation of hepatic stellate cells (HSCs) caused by a variety of chronic liver injuries. It is important to explore approaches to inhibit the activation and proliferation of HSCs for the treatment of liver fibrosis. PLK1 is overexpressed in many human tumour cells and has become a popular drug target in tumour therapy. Therefore, further study of the function of PLK1 in the cell cycle is valid. In the present study, we found that PLK1 expression was elevated in primary HSCs isolated from CCl
4
‐induced liver fibrosis mice and LX‐2 cells stimulated with TGF‐β1. Knockdown of PLK1 inhibited α‐SMA and Col1α1 expression and reduced the activation of HSCs in CCl
4
‐induced liver fibrosis mice and LX‐2 cells stimulated with TGF‐β1. We further showed that inhibiting the expression of PLK1 reduced the proliferation of HSCs and promoted HSCs apoptosis in vivo and in vitro. Furthermore, we found that the Wnt/β‐catenin signalling pathway may be essential for PLK1‐mediated HSCs activation. Together, blocking PLK1 effectively suppressed liver fibrosis by inhibiting HSC activation, which may provide a new treatment strategy for liver fibrosis.
As the result of chronic liver disease, hepatic fibrosis (HF), a wound-healing response to repeated liver injury, which is characterized by excessive deposition of extracellular matrixes (ECM). [1][2][3] Persistent HF may evolve into cirrhosis, liver failure, or even liver cancer. 4 Early HF may be halted and even reversed after withdrawal of the underlying cause of disease by intervention. 5 Moreover, it has been widely confirmed that the activation and proliferation of hepatic stellate
:
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate the expression of targets
genes by binding to the 3′-untranslated regions. They play vital roles in diverse biological processes, including the
development of hepatic fibrosis (HF). HF is characterized by the accumulation of extracellular matrix (ECM) and hepatic
stellate cells (HSCs) are considered a major cell type for producing ECM. Alteration of the HSC phenotype plays a crucial
role in the HF pathological process. miRNAs involved in various biological process, such as differentiation,
apoptosis, migration, and their relevant signaling pathways, are expressed in HSCs; however, emerging
evidence indicates that numerous miRNAs are abnormally expressed in activated HSCs. In this review, we
summarize the categorization of miRNAs in HF and describe the relationships among them. We also discuss miRNAs
recently discovered to be related to HF, and attempt to find potential miRNAs that may serve as novel biomarkers for use
in HF treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.